These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35477308)

  • 21. Synthesis and evaluation of airway targeted PLGA nanoparticles for drug delivery in obstructive lung diseases.
    Vij N
    Methods Mol Biol; 2012; 906():303-10. PubMed ID: 22791443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in nano-based drug delivery systems for the management of cytokine influx-mediated inflammation in lung diseases.
    Gulati N; Chellappan DK; MacLoughlin R; Gupta G; Singh SK; Oliver BG; Dua K; Dureja H
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):3695-3707. PubMed ID: 38078921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineered Hybrid Nanoparticles for On-Demand Diagnostics and Therapeutics.
    Nguyen KT; Zhao Y
    Acc Chem Res; 2015 Dec; 48(12):3016-25. PubMed ID: 26605438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilizing the Lung as a Model to Study Nanoparticle-Based Drug Delivery Systems.
    McDaniel DK; Ringel-Scaia VM; Coutermarsh-Ott SL; Allen IC
    Methods Mol Biol; 2018; 1831():179-190. PubMed ID: 30051432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and Evaluation of Airway-Targeted PLGA-PEG Nanoparticles for Drug Delivery in Obstructive Lung Diseases.
    Vij N
    Methods Mol Biol; 2020; 2118():147-154. PubMed ID: 32152977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease.
    De Rubis G; Paudel KR; Corrie L; Mehndiratta S; Patel VK; Kumbhar PS; Manjappa AS; Disouza J; Patravale V; Gupta G; Manandhar B; Rajput R; Robinson AK; Reyes RJ; Chakraborty A; Chellappan DK; Singh SK; Oliver BGG; Hansbro PM; Dua K
    Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):2793-2833. PubMed ID: 37991539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations.
    Ngan CL; Asmawi AA
    Drug Deliv Transl Res; 2018 Oct; 8(5):1527-1544. PubMed ID: 29881970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lung disease and PKCs.
    Dempsey EC; Cool CD; Littler CM
    Pharmacol Res; 2007 Jun; 55(6):545-59. PubMed ID: 17582782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanomedicine in pulmonary delivery.
    Mansour HM; Rhee YS; Wu X
    Int J Nanomedicine; 2009; 4():299-319. PubMed ID: 20054434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoparticle-Based Inhalation Therapy for Pulmonary Diseases.
    Yadav D; Wairagu PM; Kwak M; Jin JO
    Curr Drug Metab; 2022; 23(11):882-896. PubMed ID: 35927812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutrophil targeted nano-drug delivery system for chronic obstructive lung diseases.
    Vij N; Min T; Bodas M; Gorde A; Roy I
    Nanomedicine; 2016 Nov; 12(8):2415-2427. PubMed ID: 27381067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanoparticle-mediated pulmonary drug delivery: state of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections.
    Huang Z; Kłodzińska SN; Wan F; Nielsen HM
    Drug Deliv Transl Res; 2021 Aug; 11(4):1634-1654. PubMed ID: 33694082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery.
    Yhee JY; Im J; Nho RS
    J Clin Med; 2016 Sep; 5(9):. PubMed ID: 27657144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanoparticle formulations in pulmonary drug delivery.
    Bailey MM; Berkland CJ
    Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential.
    Vij N
    Expert Opin Drug Deliv; 2011 Sep; 8(9):1105-9. PubMed ID: 21711085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the Toxicity, Lung Distribution, and Cellular Uptake of Rifampicin and Ascorbic Acid-Loaded Alginate Nanoparticles as Therapeutic Treatment of Lung Intracellular Infections.
    Scolari IR; Volpini X; Fanani ML; La Cruz-Thea B; Natali L; Musri MM; Granero GE
    Mol Pharm; 2021 Mar; 18(3):807-821. PubMed ID: 33356316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in lipid-based pulmonary nanomedicine for the management of inflammatory lung disorders.
    Kumar M; Jha A; Bharti K; Parmar G; Mishra B
    Nanomedicine (Lond); 2022 May; 17(12):913-934. PubMed ID: 35451334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advancements in Chitosan-Based Nanoparticles for Pulmonary Drug Delivery.
    Zacaron TM; Silva MLSE; Costa MP; Silva DME; Silva AC; Apolônio ACM; Fabri RL; Pittella F; Rocha HVA; Tavares GD
    Polymers (Basel); 2023 Sep; 15(18):. PubMed ID: 37765701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanobiotechnology-based drug delivery in brain targeting.
    Dinda SC; Pattnaik G
    Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.